Haematologica

Article	Citations
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors	108
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia	106
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia	99
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	82
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t	77
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	74
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide	69
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition	67
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma	64
Leukemic stem cells and therapy resistance in acute myeloid leukemia	62
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT	58
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia	58
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients	56
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma	51
Targeting the tumor microenvironment in chronic lymphocytic leukemia	50
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis	50
Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS	49
VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)	49
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies	49
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies	48
Post-mortem findings in vaccine-induced thrombotic thombocytopenia	48
The interactome of the N-terminus of band 3 regulates red blood cell metabolism and storage quality	46
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma	46
Red cell transfusion and alloimmunization in sickle cell disease	46
The clinical impact of the molecular landscape of acute myeloid leukemia	45

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?	44
A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol	43
Complement dysregulation is associated with severe COVID-19 illness	40
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome	39
Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood s	39
Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy	39
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis	38
Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia	36
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines	36
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma	36
Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York	36
Unique ethnic features of <I>DDX41</I> mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia	36
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter	36
IgM monoclonal gammopathies of clinical significance: diagnosis and management	34
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome	33
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study	33
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia	33
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy	33
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation	33
Successful pregnancies after transplantation of ovarian tissue retrieved and cryopreserved at time of childhood acute lymphoblastic leukemia – A case report	32
Marginal zone lymphoma: present status and future perspectives	31
Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies	31
Molecular and phenotypic diversity of <I>CBL</I>-mutated juvenile myelomonocytic leukemia	30
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study	30
Circulating histones play a central role in COVID-19-associated coagulopathy and mortality	30
COVID-19 and sickle cell disease	30
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study	29
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leuke	29
Treatment of drug-induced immune thrombocytopenias	29
Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy	29
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma	29
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia	28
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study	28
Stored blood has compromised oxygen unloading kinetics that can be normalized with rejuvenation and predicted from corpuscular side-scatter	28
The present and future of measurable residual disease testing in acute myeloid leukemia	28
Beta thalassemia minor is a beneficial determinant of red blood cell storage lesion	27
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag	27
Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia	27
Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish	27
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde	26
Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome	26
Aging of human hematopoietic stem cells is linked to changes in Cdc42 activity	25
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis	24
T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective	23
Deregulation of JAK2 signaling underlies primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T-cell lymphoma	23
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia	23
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)	23
Prevention and management of secondary central nervous system lymphoma	22
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute	22
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma	22

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients	22
Novel immunotherapies in multiple myeloma – chances and challenges	22
A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia	22
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study	22
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study	22
Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma	22
Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine	21
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies	21
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia	21
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia	21
Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia	21
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice	21
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies	21
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients	21
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas	21
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results	20
How I diagnose and treat chronic myelomonocytic leukemia	20
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panel	20
The TRPV2 channel mediates Ca2+ influx and the Δ9-THC-dependent decrease in osmotic fragility in red blood cells	20
The Hsp70 chaperone system: distinct roles in erythrocyte formation and maintenance	20
Crucial role of hematopoietic <i>JAK2</i> V617F in the development of aortic aneurysms	20
Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis	20
Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis	20
Towards manufactured red blood cells for the treatment of inherited anemia	20
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma	20
The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma	19
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?	19
Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab	19
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial	19
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia	19
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model	19
Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study	19
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia	19
Genotype-phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort	19
The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial	19
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results	19
PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia	19
Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing	19
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project	18
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia	18
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation	18
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia	18
Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets	18
Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes	18
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination	18
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome	18
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial	18
Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation	18
New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia	18
Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia	18
A novel classification of hematologic conditions in patients with Fanconi anemia	18
Time for an individualized approach to first-line management of follicular lymphoma	18
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications	18
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis	17
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial	17
Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia	17
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study	17
Baseline SUV<sub>max</sub> is related to tumor cell proliferation and patient outcome in follicular lymphoma	17
Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis	17
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells	17
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma	17
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study	17
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib	17
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications	17
Dominance of an <i>UBA1</i> mutant clone over a <i>CALR</i> mutant clone: from essential thrombocytemia to VEXAS.	16
Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant	16
The gut microbiome in patients with chronic lymphocytic leukemia	16
Mitochondrial ATP generation in stimulated platelets is essential for granule secretion but dispensable for aggregation and procoagulant activity	16
Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation	16
Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia	16
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial	16
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	16
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients	16
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients	16
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential	16
Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden	16
Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis	16
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis	16
Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial	16
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA	16

A risk score based on real-world data to predict early death in acute promyelocytic leukemia	16
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy	15
<i>DUSP22</i> rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma	15
The “7+3” regimen in acute myeloid leukemia	15
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study	15
Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome	15
Post-translational polymodification of β1-tubulin regulates motor protein localization in platelet production and function	15
A mutation in the iron-responsive element of <i>ALAS2</i> is a modifier of disease severity in a patient suffering from <i>CLPX</i> associated erythropoietic protoporphyria	15
The relative importance of platelet integrins in hemostasis, thrombosis and beyond	15
SARS-CoV-2 infection in aplastic anemia	15
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome	15
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities	15
Successful gene therapy of Diamond-Blackfan anemia in a mouse model and human CD34<sup>+</sup> cord blood hematopoietic stem cells using a clinically applicable lentiviral vector	15
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial	15
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy	15
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias	15
Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way	15
Fusion gene detection by RNA-sequencing complements diagnostics of acute myeloid leukemia and identifies recurring <i>NRIP1-MIR99AHG</i> rearrangements	14
Hypoxia-inducible erythropoietin expression: details matter	14
Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants	14
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells	14
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas	14
Therapeutic potential of ruxolitinib and ponatinib in patients with <i>EPOR</i>-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia	14
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase	14
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma	14
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study	14
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia	14
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study	14
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials	14
Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T-cell leukemia	14
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study	14
Prospects in the management of patients with follicular lymphoma beyond first-line therapy	14
A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas	14
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma	14
High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL	14
A Pin1/PML/P53 axis activated by retinoic acid in <i>NPM-1c</i> acute myeloid leukemia	13
Pure erythroid leukemia is characterized by biallelic <i>TP53</i> inactivation and abnormal p53 expression patterns in <i>de novo</i> and secondary cases	13
Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children	13
UBA6 and NDFIP1 regulate the degradation of ferroportin	13
GNE-related thrombocytopenia: evidence for a mutational hotspot in the ADP/substrate domain of the GNE bifunctional enzyme	13
Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19	13
Immunologic characterization of COVID-19 patients with hematological cancer	13
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphom	13
A prognostic index predicting survival in transformed Waldenström macroglobulinemia	13
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia	13
Mobilization efficiency is critically regulated by fat via marrow PPARδ	13
APOLD1 loss causes endothelial dysfunction involving cell junctions, cytoskeletal architecture, and Weibel-Palade bodies, while disrupting hemostasis	13
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study	13
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease	13
YTHDF3 modulates hematopoietic stem cells by recognizing RNA m<sup>6</sup>A modification on <i>Ccnd1</i>	13
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial	13
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas	13
Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance	13
Human erythroid differentiation requires VDAC1-mediated mitochondrial clearance	13
Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology	13
Recognition of thrombotic risk of thrombocytosis in iron deficiency	13
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma	13
Critical role of peroxisome proliferator-activated receptor α in promoting platelet hyperreactivity and thrombosis under hyperlipidemia	12
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) an	12
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers	12
Loss of interleukin-10 activates innate immunity to eradicate adult T-cell leukemia-initiating cells	12
Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of <i>ex vivo</i> treated pediatric T-cell acute lymphoblastic leu	12
Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux	12
Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC)	12
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation	12
Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells <i>in vivo</i>	12
Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients	12
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma	12
Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations	12
ALK-negative anaplastic large cell lymphoma with <i>DUSP22</i> rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study	12
Somatic genetic alterations predict hematological progression in GATA2 deficiency	12
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning	12
Immune thrombocytopenia following vaccination during the COVID-19 pandemic	11
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival	11
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib	11
Increased retention of functional mitochondria in mature sickle red blood cells is associated with increased sickling tendency, hemolysis and oxidative stress	11
Loss of <I>Nupr1</I> promotes engraftment by tuning the quiescence threshold of hematopoietic stem cells via regulation of the p53-checkpoint pathway	11
Comparative analysis of oral and intravenous iron therapy in rat models of inflammatory anemia and iron deficiency	11
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort	11
The post-hematopoietic cell transplantation microbiome: relationships with transplant outcome and potential therapeutic targets	11
Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis	11
Inhibition of DAGLβ as a therapeutic target for pain in sickle cell disease	11
Effects of nandrolone decanoate on telomere length and clinical outcome in patients with telomeropathies: a prospective trial	11
The GPIbα intracellular tail - role in transducing VWF- and collagen/GPVI-mediated signaling	11
Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden	11
Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient	11
One third of alloantibodies in patients with sickle cell disease transfused with African blood are missed by the standard red blood cell test panel	11
Chronic organ injuries in children with sickle cell disease	11
Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways	11
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017	11
Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect	11
Somatic <I>STAT3</I> mutations in CD8<sup>+</sup> T cells of healthy blood donors carrying human T-cell leukemia virus type 2	11
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia	10
Vaccine-induced immune thrombotic thrombocytopenia: a possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein	10
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels	10